Case Study

提供全天候监管支持，同时提升团队凝聚力

Advaxis Inc. is devoted to the discovery, development, and commercialization of immunotherapies based on a…

Certara2022 年 6 月 3 日

Case Study

PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA

In 2020, the US FDA approved Risdiplam (Evrysdi®) as the first orally administered drug to…

Certara2022 年 6 月 2 日

Announcement

P21 Adds Support for CDISC Open Rules Engine (CORE)

P21 is proud to announce that support for CDISC Open Rules Engine (CORE) is now available…

Certara2022 年 4 月 25 日

Announcement

Pinnacle 21 Releases P21 Community 4.0

As of 2022 年 4 月 25 日, we have released P21 Community 4.0 to general availability! Install…

Certara2022 年 4 月 25 日

Case Study

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to…

Certara2022 年 4 月 11 日

Conference

ASCPT 2026 Annual Meeting

Certara2022 年 3 月 7 日

Announcement

P21 Releases New PMDA Validation Engine

New PMDA Engine Pinnacle 21 is happy to announce the latest Validation Engine for submissions…

Certara2021 年 12 月 20 日

Blog

Industry Metrics for CDISC Controlled Terminology

Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture…

Certara2021 年 11 月 17 日

White Paper

运用真实世界证据推动新疗法市场准入

Certara2021 年 9 月 29 日

On-Demand Webinar

罕见病管理的“可怕”未来

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

Certara2021 年 9 月 23 日

Certara 产品

提供全天候监管支持，同时提升团队凝聚力

PBPK Modeling in Adults Enables DDI Risk Assessment in Children with SMA

P21 Adds Support for CDISC Open Rules Engine (CORE)

Pinnacle 21 Releases P21 Community 4.0

PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials

ASCPT 2026 Annual Meeting

P21 Releases New PMDA Validation Engine

Industry Metrics for CDISC Controlled Terminology

运用真实世界证据推动新疗法市场准入

罕见病管理的“可怕”未来

订阅时事通讯

快捷链接

解决方案

联系我们